All Articles

Understanding your role (and setting boundaries) allows you to remain focused on the tenets of oncology navigation—providing compassionate patient-centered care.

An Interview with Joanita Miranda, MSW, LCSW, OSW-C

Pivotal phase 3 data demonstrated treatment with luspatercept resulted in statistically significant increased red blood cell transfusion independence compared with placebo.

On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020.

Have you identified a gap in care, a gap in knowledge, or a problem in your clinical practice that needs solving? What tactics have you implemented in your practice setting that have improved patient care? What circumstance inspired you to make a change in your practice?

The authors reveal how they were able to increase the number of identified barriers to care for their oncology patients.

New cases of male breast cancer are up by 22% and the mortality rate has increased by 19%. Here’s what The Male Breast Cancer Coalition is doing about it.

Eye-opening comments from the people who stand to benefit from navigation most. Here’s what they said.